New York, September 10, 2015 -- Moody's Investors Service commented that the resolution of the FDA warning letter is credit positive for Impax Laboratories, Inc. (Impax). There is no change to Impax's B1 Corporate Family Rating or stable outlook. Please go to www.moodys.com for our full issuer comment.
Vollständigen Artikel bei Moodys lesen